# Role of first Trimester Maternal Serum Uric Acid Concentration in Prediction of Gestational Diabetes

Thesis

Submitted for partial fulfillment of master degree of family medicine

# Presented by **Eman Samy Mohammed**

Resident of family medicine -Damietta - M.B.B.Ch

**Under Supervision of** 

### **Prof. Iman Mohamed Ahmed Bakr**

Professor of community, Environmental and Occupational Medicine

Faculty of Medicine - Ain Shams University

### **Prof. Samia Mohamad Eid**

Professor of Obstetrics and Gynecology

Faculty of Medicine – Al Azhar University (Damietta)

# **Dr. Amany Mohamed Sayed**

Lecturer of Community, Environmental and Occupational Medicine

Faculty of medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
2016



First of all, all thanks to Allah gives me the power to complete this work.

I wish to express my deepest sincere thanks to **Prof. Iman Mohamed Ahmed**Bakr, Professor in the department of community, Environmental and Occupational
Medicine Faculty of Medicine - Ain Shams University for her guidance, great help
and support throughout supervising this work.

I would like to express my deepest sincere thanks to **Prof. Samia Mohammed Eid,** Professor of Obstetrics and Gynecology, Faculty of Medicine Al-Azhar
University (Damietta), for her guidance and support throughout supervising this
work.

My deepest appreciation to **Dr. Amany Mohamed Sayed**, Lecturer in the Department of Community, Environmental and Occupational Medicine Faculty of medicine - Ain Shams university for her guidance and support throughout supervising this work.

# **Table of contents**

Subject	Page
Introduction	
Aim of the study	4
Review of literature	
Gestational diabetes	5
Uric acid	19
Prediction and prevention of GDM	23
Gestational Diabetes Guidelines for Family physician	47
Subjects and methods	
Results	56
Discussion	
Summary	
Conclusion	78
Recommendation	79
References	80
Arabic summary	-

# List of abbreviations

AMP Ade AMPK Ade BIAsp Bip BMI Boo CFU Col CGMS Cor	nerican diabetes association enylic acid enosine monophosphate-activated protein kinase chasic insulin aspart dy mass index lony forming unit ntinuous glucose monitoring systems ildhood Autism Risks from Genetics and the Environment infidence interval
AMPK Ade BIAsp Bip BMI Boo CFU Col CGMS Cor	enosine monophosphate-activated protein kinase ohasic insulin aspart dy mass index lony forming unit ntinuous glucose monitoring systems ildhood Autism Risks from Genetics and the Environment nfidence interval
BIAsp Bip BMI Boo CFU Col CGMS Cor	ohasic insulin aspart dy mass index lony forming unit ntinuous glucose monitoring systems ildhood Autism Risks from Genetics and the Environment nfidence interval
BMI Boo CFU Col CGMS Cor	dy mass index lony forming unit ntinuous glucose monitoring systems ildhood Autism Risks from Genetics and the Environment nfidence interval
CFU Col CGMS Cor	lony forming unit ntinuous glucose monitoring systems ildhood Autism Risks from Genetics and the Environment nfidence interval
CGMS Cor	ntinuous glucose monitoring systems ildhood Autism Risks from Genetics and the Environment nfidence interval
	ildhood Autism Risks from Genetics and the Environment nfidence interval
CHARGE Chi	nfidence interval
CI Cor	
DKA Dia	abetic ketoacidosis
DM Dia	abetes mellitus
DNA Dec	oxyribonucleic acid
FDA Foo	od and Drug Administration
FPG Fast	sting plasma glucose
GAD Glu	ntamic acid decarboxylase
GDM Ges	stational diabetes mellitus
GFR Glo	omerular filtration rate
HAPO Hyp	perglycemia and Adverse Pregnancy
HbA1c Gly	vcosylated hemoglobin
IADPSG The	e International Association of the Diabetes and Pregnancy Study Groups
IMP Inos	sinic acid
IRS-1 Insu	ulin receptor substrate-1
IU Inte	ernational unit
LGA Lar	ge-for-gestational age
MODY Mat	turity onset diabetes of the young.
MPC Moo	odel predictive control
NCCWCH Nat	tional Collaborating Centre for Women's and Children's Health
NDDG Nat	tional Diabetes Data Group
NHS Nat	tional Health Service
NICE Nat	tional institute for health and care excellence
NPH Neu	utral Protamine Hagedorn (Humolin; long acting insulin).
OGTT Ora	al glucose tolerance test
OHAs Ora	al hypoglycemic agents
OR Odd	ds ratio
PKA acid	d dissociation constant
PE Pre-	-eclampsia
PCOS Poly	y cystic ovary syndrome
RHI Reg	gular human insulin
T1DM Typ	pe-1 diabetes mellitus
T2DM Typ	pe-2 diabetes mellitus
TB Tub	berculosis
TRIGR Tria	al to Reduce Insulin-dependent Diabetes Mellitus in the Genetically At Risk
·	ited kingdom
	orld health organization

# List of tables

n.	Title	Page
1	Classification of DM complicating pregnancy.	12
2	Current screening and diagnostic strategies of GDM.	35
3	Tests for gestational diabetes.	36
4	Diagnostic criteria for GDM.	39

# List of tables of results

n.	Title	Page
1	Sociodemographic data for the studied group	56
2	Obstetrical, gynaglogical, family and past medical history of	57
	studied group.	
3	Measurements and laboratory investigations done for the	58
	studied group in first trimester (10- 13 wks).	
4	Laboratory investigations done for the studied group in	59
	second trimester (24-26) wks.	
5	The relationship between level of uric acid in the first	60
	trimester and developing of GDM in the second trimester.	
6	Incidence of GDM and risk estimate of hyperuricemia in	61
	studied populations	
7	Mean age among those with and without GDM.	62
8	Relationship between sociodemographic data and the	63
	development of GDM among the studied group.	
9	Relationship between the obstetrical history and development	64
	of GDM among the studied group.	
10	Relationship between Family and past history in studied	65
	group and development of GDM.	
11	Body mass index (BMI) in studied populations	66
12	Uric acid concentration in studied populations.	67
13	Sensitivity and specificity of uric acid in prediction of	68
	GDM	
14		69
	Correlation between uric acid and fasting blood sugar	
15	Logistic regression for significant variables.	69

# **List of figures**

n.	Title	Page
1	Uric acid concentration in studied populations	61
2	Specificity roc curve	68

#### Role of first Trimester Maternal Serum Uric Acid Concentration in Prediction of Gestational Diabetes

#### **ABSTRACT**

Prof. Iman Mohamed Ahmed Bakr, Prof. Samia Mohamad Eid,prof.Aisha Abo elfottoh,Prof Lila Abd Elrehim,Dr .amany elsaid,Eman samy

Faculty of Medicine – Ain Shams University

#### **Introduction:**

. Women who have had GDM are much more likely to develop type 2 DM later in life. Polyhydramnios, preterm labor, pyelonephritis, hypertension and preeclampsia were more frequent in GDM. Maternal hyperglycemia leads to intrauterine hyperglycemia, fetal hyper- insulinemia, shoulder dystocia, hyperbilirubinaemia, respiratory distress syndrome birth injuries, perinatal mortality, polycythaemia, caesarean delivery and congenital anomalies we use new method for screeninig of GDM **Materials and Methods** Cohort study, carried out in the period between March 2015 and April 2016. Pregnant women at first trimester (10-13wks) susceptible to diabetes mellitus attending Al-azhar University Hospital (Damietta) at department of Obstetrics and Gynecology.

. **Results**:The majority of females (80.9%) were from rural area.47.9% had primary education;66% of females were housewives;age ranged from 18 to 45 years with mean of  $27.08\pm5.80$  years. Females developed gestational diabetes mellitus were 31 cases (33.3%).There is strong association between high uric acid level in 1<sup>st</sup> trimestr and subsequent development of GDM in 3<sup>rd</sup> trimestr with R.R 4.1. The mean age of those who suffered from GDM was significantly hiegher than those who were free from it (29.25 $\pm5.65$  vs  $26.01\pm5.61$  respectively).

Women with positive family history for hypertension and with past history of GDM suffered from GDM at a higher level than those with negative history and the difference was statistically significant.

Although those who had a positive family history of diabetes had a higher level of developing GDM, yet the relation didn't reach the level of the of the statistically significant difference.

The BMI ranged from 22.20 to 72.20 with mean of  $32.99\pm6.70 \text{ kg/m}^2$ ; and there was significant obesity in positive GDM group when compared to negative GDM group ( $36.36\pm6.27 \text{ vs } 31.33\pm6.08 \text{ respectively}$ ).

The serum uric acid ranged from 1.2 to 6.60 with a mean of 3.71±1.19 mg/dl; and there was a significant increase of uric acid conc in positive GDM group when compared to negative GDM group (4.48±0.84 vs 3.33±1.16 respectively). Conclusion Elevated first-trimester uric acid concentration was correlated with an increased risk of developing GDM. The risk of developing GDM was 4-fold higher if first-trimester uric acid was ≥ 4mg/dl. The mean BMI was significantly higher in women who when compared women who developed **GDM** to did not develop GDM[(36.36±6.27vs31.33±6.08 respectively). The mean age of those who suffered from GDM was significally hiegher than those who were free from it (29.25±5.65 vs 26.01±5.61 respectively)

**Key words:** gestational diabetes, Uric acid, screening .family medicine



# Introduction and Aim of the work

## Introduction

Gestational diabetes mellitus (GDM), defined as two or more elevated glucose values obtained during a 3-hours oral glucose tolerance test (OGTT) (WHO, 1999). It affects between 17-27% of pregnancies depending on diagnostic criteria and population (Gollenberg et al., 2010). GDM is one of the most common medical disorders during pregnancy (Vibeke et al., 2008).

GDM prevalence has increased in several racial and ethnic groups during the past 20 year (**Horvath et al., 2010**). The prevalence of GDM in, the US (4.8%) (**Keshavarz et al., 2005**), France (12.1%) (**Schneider et al., 2010**) Canada (17.8%) (**Ryan, 2011**), and Australia (9.5%) (**Moses et al., 2011**).

The prevalence in Arab countries is consider high as Qatar was 16.3%; In the United Arab Emirates (20.6%) (**Agarwal et al., 2007**) and in Bahrain and Saudi Arabia (12.5%) (**Horvath et al., 2010**).

Women who have had GDM are much more likely to develop type 2 DM later in life. Polyhydramnios, preterm labor, pyelonephritis, hypertension and preeclampsia were more frequent in GDM. Maternal hyperglycemia leads to intrauterine hyperglycemia, fetal hyperinsulinemia, shoulder dystocia, hyperbilirubinaemia, respiratory distress syndrome birth injuries, perinatal mortality, polycythaemia, caesarean delivery and congenital anomalies (**Ryan, 2011**).

Renal vein thrombosis has also been reported to result from polycythaemia. The fetal lung maturation will be delayed in diabetics (Cheema et al., 2010).

GDM is associated with poor pregnancy outcomes; also less severe forms of glucose intolerance are associated with increased feto-maternal morbidity (**Shand et al.,** 2008). Perinatal mortality was noted in approximately 2.8% and congenital malformations in 6.4% (**Horvath et al., 2010**).

The complications associated with GDM can affect both the mother and the fetus which can be avoided by early prediction (**Dabela et al.**, 2005). Several studies have now shown that, compared to their peers, women who go on to develop GDM later in pregnancy have biochemical abnormalities that can be detected in the first trimester including increased levels of uric acid (**Hedderson et al.**, 2008).

Uric acid is the end product of purine metabolism and is synthesized by the enzyme xanthine oxidas (**Dincer et al., 2002**): Uric acid is associated with insulin resistance in non pregnant women (**Modan et al., 1987**).

Outside of pregnancy, hyperuricemia is also associated with the markers of metabolic syndrome, including obesity and dyslipidemia (Güngör et al., 2006).

Uric acid is an independent risk factor for developing type-2 diabetes within 10 years in non-pregnant women, an association that was stronger in women compared to men (Masuo et al., 2010).

During pregnancy, the glomerular filtration rate (GFR) increases by ~50%, thereby decreasing the serum creatinine and the uric acid levels. However, the creatinine levels towards the upper limit of the normal range are a warning sign of impending renal disease in GDM. The raised uric acid levels in GDM are a component of the metabolic syndrome that reflects insulin resistance (Masuo et al., 2010).

Alongside the development of new guidance for diabetes in pregnancy concluded that screening and treatment for GDM was cost-effective for the National Health Service (NHS) (Coutinho et al., 2007).

The American Diabetes Association, the American College of Obstetricians and Gynecologists, and the World Health Organization recommend screening most pregnant women for gestational diabetes between 24 and 28 weeks' gestation and screening high-risk pregnant women (Jensen et al., 2011).

The Hyperglycemia and Adverse Pregnancy outcome (HAPO) group sought to identify new screening values that would better identify pregnancies at risk for perinatal complications. The HAPO study demonstrated a positive linear relationship between screening glucose values and adverse perinatal outcomes (NCCWCH, 2008).

Some groups have demonstrated that current screening protocols fail to identify many at-risk pregnancies (Landon et al., 2011).

Given the many changes that adopting a new strategy for GDM screening may have on our health care system, it is critical to assess the costs and effects of the approach, it would impact over 4 million pregnant women and result in over 500,000 additional diagnoses of GDM annually in the U.S. alone (Cowie et al., 2010). Also there is a gap of knowledge about the relation between both of uric acid and GDM, we go on through this study aiming to increase our knowledge about it.

# Aim of the study

The aim of this study is to determine the role of first trimester maternal serum uric acid concentration in predicting the subsequent development of gestational diabetes mellitus for high risk female.



# Review of Literature

#### **Gestational diabetes**

Gestational diabetes is defined as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy whether or not insulin is used for treatment (ACOG, 2013). It is diagnosed by two or more elevated glucose values obtained during a 3-hours oral glucose tolerance test (OGTT) (WHO, 1999).

#### **Epidemiology:**

GDM prevalence has increased in several racial and ethnic groups during the past 20 year (**Horvath et al., 2010**). The prevalence of GDM in, the US (4.8%) (**Keshavarz et al., 2005**), France (12.1%) (**Schneider et al., 2010**) Canada (17.8%) (**Ryan, 2011**), and Australia (9.5%) (**Moses et al., 2011**).

The prevalence in Arab countries is consider high as Qatar was 16.3%; In the United Arab Emirates (20.6%) (**Agarwal et al., 2007**) and in Bahrain and Saudi Arabia (12.5%) (**Horvath et al., 2010**).

The number of adults diagnosed with diabetes in the United States has tripled from 6.9 million in 1991 to 20.9 million in 2011. Diabetes mellitus is the commonest medical condition complicating pregnancy, affecting up to 5% of pregnancies in England and up to 25% of pregnancies in Asia. Prevalence of GDM is increasing all over the world due to increased incidence of risk factors for the development of GDM (Bellamy et al., 2009).

#### **Risk factors:**

 Women with a history of gestational diabetes have also increased risk of developing gestational diabetes in subsequent pregnancies (Bottalico, 2007)